Bio

David Baker is an American biochemist and computational biologist, born October 6, 1962 in Seattle, Washington. He is the Henrietta and Aubrey Davis Endowed Professor in Biochemistry at the University of Washington, an investigator with the Howard Hughes Medical Institute, and director of the University of Washington Institute for Protein Design. He is a co-recipient of the 2024 Nobel Prize in Chemistry, awarded one half of the prize "for computational protein design", with the other half shared between Demis Hassabis and John M. Jumper of Google DeepMind for the development of AlphaFold 2. Baker is a co-founder of Xaira Therapeutics, the AI-driven drug-discovery company launched in April 2024 with more than $1 billion in committed capital, and a co-founder of more than twenty additional biotechnology companies built on Rosetta-and-RoseTTAFold-derived protein design.

At a glance

• Education: Bachelor of Arts in biology, Harvard University (1984); PhD in biochemistry, University of California, Berkeley (1989), advised by Randy Schekman; postdoctoral biophysics training at the University of California, San Francisco under David Agard (1989 to 1993).
• Current roles: Henrietta and Aubrey Davis Endowed Professor in Biochemistry, University of Washington (since 1993); director of the University of Washington Institute for Protein Design (since 2012); investigator with the Howard Hughes Medical Institute (since 2000); co-founder of Xaira Therapeutics (April 2024).
• Key contributions: the Rosetta algorithm for protein structure prediction (1998); Rosetta@home distributed computing project (2004); Foldit citizen-science protein-folding game (2008); de novo protein design including the 2003 Top7 protein; RoseTTAFold (2021); RFdiffusion (2023); RFdiffusion All-Atom (2024).
• Awards: 2024 Nobel Prize in Chemistry; Breakthrough Prize in Life Sciences (2021); Frontiers of Knowledge Award (2022); Wiley Prize in Biomedical Sciences (2022); Sjöberg Prize (2024); member of the National Academy of Sciences and the National Academy of Engineering.
• Wikipedia: David Baker (biochemist)
• Lab page: bakerlab.org

Origins

Baker was born on October 6, 1962 in Seattle, Washington. His parents were both faculty at the University of Washington: his father Marshall Baker a physicist and his mother Marcia Baker an atmospheric scientist and physicist. He attended Garfield High School in Seattle before moving east for undergraduate studies.

He matriculated at Harvard University in 1980, where he initially intended to study social studies and philosophy before being drawn into biology through Edward O. Wilson's evolutionary-biology course. He completed a Bachelor of Arts in biology in 1984. He moved to the University of California, Berkeley for doctoral studies in biochemistry, completing a PhD in 1989 under the supervision of Randy Schekman (subsequently a 2013 Nobel laureate in Physiology or Medicine for cellular vesicle transport). His doctoral thesis investigated protein transport mechanisms in yeast.

After Berkeley, Baker spent four years as a postdoctoral fellow in biophysics at the University of California, San Francisco under David Agard, studying protein folding. The UCSF period set the research direction that would dominate the rest of his career: the prediction and design of three-dimensional protein structures from amino-acid sequences, a problem that had remained one of the central open questions in molecular biology since Christian Anfinsen's 1972 Nobel-cited articulation of the protein-folding problem.

Career

Baker joined the University of Washington Department of Biochemistry as faculty in 1993, where he has remained for the entirety of his subsequent career. He became a Howard Hughes Medical Institute investigator in 2000 and the founding director of the University of Washington Institute for Protein Design in 2012. He holds the Henrietta and Aubrey Davis Endowed Professorship in Biochemistry and adjunct appointments in genome sciences, bioengineering, chemical engineering, computer science, and physics, reflecting the cross-disciplinary scope of the protein-design research program.

The defining research artifact of Baker's first decade at Washington was the Rosetta algorithm, which his group developed beginning in 1998 for predicting protein structures from amino-acid sequences. Rosetta first attracted broad attention at the third biennial Critical Assessment of Protein Structure Prediction (CASP) competition in 1998, where it produced state-of-the-art results. The algorithm was subsequently extended to protein design, where the structure-prediction methodology is run in reverse to compute amino-acid sequences that fold into specified target structures. The 2003 paper "Design of a Novel Globular Protein Fold with Atomic-Level Accuracy" with Brian Kuhlman and others reported Top7, the first protein designed entirely de novo and verified experimentally to fold to its computationally specified structure.

In 2004 Baker launched Rosetta@home, a distributed-computing project that allowed volunteers to contribute idle CPU cycles to running Rosetta calculations. By early 2008 nearly 200,000 volunteers had downloaded the project, providing computational resources at a scale that exceeded what was practical with university-cluster computing alone. The 2008 launch of Foldit, a multiplayer online protein-folding game built with Seth Cooper and others at Washington's Center for Game Science, extended the citizen-science model into a structured human-computer collaboration. Foldit players have repeatedly out-performed pure-algorithmic Rosetta runs on specific protein-prediction problems, including a widely cited 2011 result on a retroviral protease structure that had resisted algorithmic approaches.

Through the 2010s, Baker's research program produced an expanding sequence of de novo protein-design results, including artificial enzymes, vaccine immunogens, signaling proteins, and structural materials. The 2021 paper "Accurate prediction of protein structures and interactions using a three-track neural network" with Minkyung Baek and others introduced RoseTTAFold, a deep-learning-based protein-structure-prediction system that drew explicit inspiration from Google DeepMind's AlphaFold 2 and was published in Science the same month AlphaFold 2 was published in Nature. RoseTTAFold made the underlying methodology openly available to the structural-biology community.

The 2023 paper "De novo design of protein structure and function with RFdiffusion" with Joseph Watson, David Juergens, and others introduced RFdiffusion, a generative diffusion model that produces novel protein backbones conditioned on functional specifications. RFdiffusion and its successors RFdiffusion All-Atom (2024) and RoseTTAFold All-Atom (2024) have been characterized in industry coverage as the principal generative-AI method for de novo protein design alongside Meta AI's ESM family and EvolutionaryScale's ESM-3.

The October 2024 Nobel Prize in Chemistry awarded one half of the prize to Baker "for computational protein design" and the other half jointly to Demis Hassabis and John Jumper of Google DeepMind "for protein structure prediction" through AlphaFold 2.

In April 2024, Baker co-founded Xaira Therapeutics with Marc Tessier-Lavigne (Chief Executive Officer; former Stanford University president and former Genentech Chief Scientific Officer), Hetu Kamisetty (former Meta and University of Washington Institute for Protein Design), and Vik Bajaj (Foresite Labs Co-Founder and Chief Executive Officer). The launch closed more than $1 billion in initial committed capital, the largest initial financing in ARCH Venture Partners history, and the company is built on Baker's protein-design research with RFdiffusion and RFantibody as the principal AI methods.

Affiliations

• University of California, San Francisco: Postdoctoral fellow under David Agard, 1989 to 1993.
• University of Washington: Faculty, 1993 to present.
• Howard Hughes Medical Institute: Investigator, 2000 to present.
• University of Washington Institute for Protein Design: Founding director, 2012 to present.
• Xaira Therapeutics: Co-founder, April 2024 to present.

Notable contributions

Baker has authored more than 600 scientific papers and is a co-founder of more than twenty biotechnology companies built on Rosetta-and-RoseTTAFold-derived protein design.

• Rosetta algorithm (1998 onward). The original computational framework for protein structure prediction and design, developed at the University of Washington and made widely available through the RosettaCommons consortium of academic laboratories.
• Top7 de novo protein (November 2003). "Design of a Novel Globular Protein Fold with Atomic-Level Accuracy" with Brian Kuhlman and others. The first protein designed entirely de novo and verified experimentally to fold to its computationally specified structure.
• Rosetta@home (2004). Distributed-computing project leveraging volunteer CPU cycles for Rosetta calculations.
• Foldit (2008). Multiplayer online protein-folding game built with the University of Washington Center for Game Science. Foldit players have repeatedly out-performed pure-algorithmic Rosetta runs on specific protein-prediction problems.
• De novo protein design pipeline (2010s onward). Sustained research output on artificial enzymes, vaccine immunogens, signaling proteins, structural materials, antibodies, and protein binders.
• RoseTTAFold (July 2021). "Accurate prediction of protein structures and interactions using a three-track neural network" with Minkyung Baek and others. Deep-learning-based protein-structure-prediction system openly released to the structural-biology community.
• RFdiffusion (July 2023). "De novo design of protein structure and function with RFdiffusion" with Joseph Watson, David Juergens, and others. Generative diffusion model for de novo protein design.
• Xaira Therapeutics co-founding (April 2024). Co-founder of the AI-driven drug-discovery company launched with more than $1 billion in committed capital.
• 2024 Nobel Prize in Chemistry, awarded one half "for computational protein design", with the other half shared between Demis Hassabis and John Jumper of Google DeepMind for AlphaFold 2.

Honors

• Member of the National Academy of Sciences (2006); member of the National Academy of Engineering (2018); member of the American Academy of Arts and Sciences (2009).
• Howard Hughes Medical Institute Investigator (2000 onward).
• Newcomb Cleveland Prize (2008); Sackler International Prize in Biophysics (2008).
• Breakthrough Prize in Life Sciences (2021), with the $3 million prize awarded for computational protein design.
• Frontiers of Knowledge Award in Biology and Biomedicine (2022).
• Wiley Prize in Biomedical Sciences (2022).
• Sjöberg Prize (2024).
• 2024 Nobel Prize in Chemistry.

Position in the field

Baker occupies a distinctive position at the intersection of computational biology and AI for biology. The combination of more than three decades of continuous protein-design research at the University of Washington Institute for Protein Design, the open-source Rosetta and RoseTTAFold software ecosystems, the more-than-twenty co-founded biotechnology companies, and the 2024 Nobel Prize in Chemistry is unmatched among working academic biochemists. Industry coverage of the protein-design field consistently treats Baker, Demis Hassabis, and John Jumper as the three principal figures of the contemporary AI-and-biology era, with Baker carrying the longer continuous research record and the broader commercial-translation footprint.

The student-and-collaborator lineage from the Baker Lab is itself a substantial element of his influence. Researchers trained at the Institute for Protein Design have founded or hold senior roles at Xaira Therapeutics, EvolutionaryScale, Generate Biomedicines, Cyrus Biotechnology, Outpace Bio, Monod Bio, Vilya, Lila Sciences, and many others, in a pattern of academic-to-commercial translation that has produced the most active protein-design startup ecosystem to date.

The April 2024 launch of Xaira Therapeutics with Marc Tessier-Lavigne, ARCH Venture Partners, and Foresite Labs was the largest initial financing in ARCH's history and reflected the strategic premise that AI-driven protein design had reached a commercial inflection point. The 2024 Nobel Prize in Chemistry validated that premise externally and placed Baker as the senior academic-and-industrial voice of the field.

Outlook

Open questions and watchable signals over the next 6 to 18 months:

• Xaira Therapeutics pipeline progression. The pace of therapeutic-pipeline disclosures and the first clinical milestones from Xaira's in-house pipeline.
• Continued RFdiffusion and successor releases. Subsequent generative-protein-design methods from the Baker Lab and the broader RosettaCommons consortium.
• Open-source-versus-commercial balance. Whether Baker maintains the open-source distribution of Rosetta-and-RoseTTAFold-derived methods alongside the proprietary commercial development at Xaira and the more-than-twenty other co-founded biotechnology companies.
• Competition with Google DeepMind AlphaFold and Isomorphic Labs. The competitive dynamics between the Baker-anchored protein-design ecosystem and the AlphaFold-anchored research-and-commercial ecosystem under Demis Hassabis.
• Public commentary and policy engagement. Continued senior public-facing engagement on AI-and-biology policy, particularly around protein-design biosecurity considerations and the broader regulation of AI-driven biology research.

Sources

• David Baker (biochemist). Wikipedia biographical entry covering education, the Rosetta-and-RoseTTAFold research program, and the 2024 Nobel Prize.
• David Baker Nobel Prize in Chemistry 2024 facts. Nobel Foundation page with the prize citation and biographical detail.
• The Nobel Prize in Chemistry 2024 press release. Nobel Foundation press release on the joint award to David Baker, Demis Hassabis, and John Jumper.
• Baker Lab. University of Washington Baker Lab page with publication list.
• University of Washington Institute for Protein Design. Institute home page.
• HHMI's David Baker Wins 2024 Nobel in Chemistry. HHMI announcement of the 2024 Nobel.
• Design of a Novel Globular Protein Fold with Atomic-Level Accuracy. The November 2003 Science paper introducing the Top7 de novo protein.
• Accurate prediction of protein structures and interactions using a three-track neural network. The July 2021 RoseTTAFold paper.
• De novo design of protein structure and function with RFdiffusion. The July 2023 RFdiffusion paper.
• The Journey to a Nobel Prize: A Protein Design and Structure Research Timeline. The Scientist coverage of the protein-design research timeline.
• Protein wrangler, serial entrepreneur, and community builder: Inside David Baker's brain. Chemical & Engineering News profile.
• Xaira Therapeutics. The April 2024 launch of the AI-driven drug-discovery company co-founded by Baker.
• RosettaCommons. The consortium of academic laboratories sharing the Rosetta software ecosystem.